发明名称 |
Companion diagnostic for CDK4 inhibitors |
摘要 |
The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. It is based, at least in part, on the discovery that cancer treatment with a CDK4 inhibitor is more effective where treated cancer cells undergo cellular senescence rather than a transient cell cycle arrest, where cellular senescence is associated with decreased MDM2 protein level. Accordingly, in non-limiting embodiments, the present invention provides for methods, compositions, and kits for a companion diagnostic for CDK4 inhibitors, and in particular, to the use of MDM2 expression as a biomarker for the likelihood that a cancer can be successfully treated by CDK4 inhibition. |
申请公布号 |
AU2014253932(A1) |
申请公布日期 |
2015.11.12 |
申请号 |
AU20140253932 |
申请日期 |
2014.04.16 |
申请人 |
MEMORIAL SLOAN-KETTERING CANCER CENTER |
发明人 |
KOFF, ANDREW W.;CRAGO, AIMEE;LIU, DAVID;KOVATCHEVA, MARTA;SINGER, SAMUEL;SCHWARTZ, GARY K.;DICKSON, MARK A.;KLEIN, MARY ELIZABETH |
分类号 |
C12Q1/68;G01N33/574 |
主分类号 |
C12Q1/68 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|